Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire · 2 hr ago
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advancesProactive Investors · Oct 8, 2026
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term ValueGlobeNewsWire · Oct 8, 2026
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDAProactive Investors · Sep 29, 2026
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate CancerGlobeNewsWire · Sep 29, 2026
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patientsProactive Investors · Sep 21, 2026Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$6.38 | -$10.50 | Miss |
| May 11, 2026 | -$9.00 | -$0.31 | Beat |
| Mar 27, 2026 | -$16.00 | -$0.51 | Beat |
| Nov 28, 2025 | -$19.00 | -$1.12 | Beat |
| Aug 14, 2025 | -$19.50 | -$0.43 | Beat |
| Jul 3, 2025 | -$19.50 | -$14.50 | Beat |